ERBB2 and neoplasm: However, in the era of anti-HER2 ADC therapies which are indicated for patients with HER2-low BCs, it is essential to develop more sensitive assays for HER2 evaluation, to harmonise scoring practices by training pathologists, and to strongly incite pathology laboratories to apply stringent quality control systems in order to better discriminate HER IHC 0 and 1+ specimens and so correctly identify HER2-low tumours so as to give a chance of treatment to all eligible patients.